161 related articles for article (PubMed ID: 16088366)
41. HIV prevalence and factors associated with HIV infection among male injection drug users under 30: a cross-sectional study in Long An, Vietnam.
Tran TM; Nguyen HT; Yatsuya H; Hamajima N; Nishimura A; Ito K
BMC Public Health; 2006 Oct; 6():248. PubMed ID: 17029648
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of attitude, risk behavior and expectations among Thai participants in Phase I/II HIV/AIDS vaccine trials.
Maek-A-Nantawat W; Pitisuttithum P; Phonrat B; Bussaratid V; Naksrisook S; Peonim W; Thantamnu N; Muanaum R
J Med Assoc Thai; 2003 Apr; 86(4):299-307. PubMed ID: 12757073
[TBL] [Abstract][Full Text] [Related]
43. Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India.
Newman PA; Chakrapani V; Weaver J; Shunmugam M; Rubincam C
Vaccine; 2014 Oct; 32(44):5854-61. PubMed ID: 25173475
[TBL] [Abstract][Full Text] [Related]
44. Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-positive injection drug users.
Dhalla S; Poole G; Singer J; Patrick DM; Kerr T
Psychol Health Med; 2012; 17(2):223-34. PubMed ID: 22250925
[TBL] [Abstract][Full Text] [Related]
45. Demographic characteristics and risk behaviors associated with HIV positive injecting drug users in Xinjiang, China.
Zhang Y; Shan H; Trizzino J; Ruan Y; Beauchamp G; Mâsse B; Ma J; Gu Y; He Y; Rui B; Wang J; Poundstone K; Jiang Y; Brooks Jackson J; Shao Y
J Infect; 2007 Mar; 54(3):285-90. PubMed ID: 16831464
[TBL] [Abstract][Full Text] [Related]
46. Injection drug users' strategies to manage perceptions of personal risk: how do IDUs see HIV as having affected them?
Smith KC; Lillie Tle L; Latkin C
AIDS Educ Prev; 2007 Jun; 19(3):245-57. PubMed ID: 17563278
[TBL] [Abstract][Full Text] [Related]
47. Knowledge and attitudes regarding preventative HIV vaccine clinical trials in Italy: results of a national survey.
Starace F; Wagner TM; Luzi AM; Cafaro L; Gallo P; Rezza G
AIDS Care; 2006 Jan; 18(1):66-72. PubMed ID: 16282079
[TBL] [Abstract][Full Text] [Related]
48. Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors.
Navaline HA; Snider EC; Petro CJ; Tobin D; Metzger D; Alterman AI; Woody GE
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S281-3. PubMed ID: 7865319
[TBL] [Abstract][Full Text] [Related]
49. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
50. Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention.
Dhalla S; Poole G
Hum Vaccin Immunother; 2014; 10(7):1974-84. PubMed ID: 25424807
[TBL] [Abstract][Full Text] [Related]
51. Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users.
Campbell JV; Garfein RS; Thiede H; Hagan H; Ouellet LJ; Golub ET; Hudson SM; Ompad DC; Weinbaum C;
Drug Alcohol Depend; 2007 Nov; 91 Suppl 1():S64-72. PubMed ID: 17276018
[TBL] [Abstract][Full Text] [Related]
52. Binge drug use independently predicts HIV seroconversion among injection drug users: implications for public health strategies.
Miller CL; Kerr T; Frankish JC; Spittal PM; Li K; Schechter MT; Wood E
Subst Use Misuse; 2006; 41(2):199-210. PubMed ID: 16393742
[TBL] [Abstract][Full Text] [Related]
53. Background demographics and risk behaviors of injecting drug users in Karachi, Pakistan.
Parviz S; Fatmi Z; Altaf A; McCormick JB; Fischer-Hoch S; Rahbar M; Luby S
Int J Infect Dis; 2006 Sep; 10(5):364-71. PubMed ID: 16793307
[TBL] [Abstract][Full Text] [Related]
54. Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein.
Luzi AM; Gallo P; Colucci A; Marcotullio S; Bellino S; Longo O; Ensoli B
AIDS Care; 2011 Aug; 23(8):939-46. PubMed ID: 21390884
[TBL] [Abstract][Full Text] [Related]
55. A quasi-experimental study on a community-based behaviour change programme among injecting drug users in Sichuan, China.
Zhou JS; Zhang KL; Zhang LL; Kang JX; Zhang JX; Lai WH; Liu L; Liu G; Zeng YL
Int J STD AIDS; 2009 Feb; 20(2):125-9. PubMed ID: 19182061
[TBL] [Abstract][Full Text] [Related]
56. Willingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in China.
Dong Y; Shen X; Guo R; Liu B; Zhu L; Wang J; Zhang L; Sun J; Zhang X; Xu J
PLoS One; 2014; 9(11):e111321. PubMed ID: 25372044
[TBL] [Abstract][Full Text] [Related]
57. HIV infection awareness and willingness to participate in future HIV vaccine trials across different risk groups in Abuja, Nigeria.
Aliyu G; Mohammad M; Saidu A; Mondal P; Charurat M; Abimiku A; Nasidi A; Blattner W
AIDS Care; 2010 Oct; 22(10):1277-84. PubMed ID: 20661789
[TBL] [Abstract][Full Text] [Related]
58. Adolescent and adult participation in an HIV vaccine trial preparedness cohort in South Africa.
Middelkoop K; Myer L; Mark D; Mthimunye SP; Smit J; Wood R; Bekker LG
J Adolesc Health; 2008 Jul; 43(1):8-14. PubMed ID: 18565432
[TBL] [Abstract][Full Text] [Related]
59. Willingness to participate in HIV vaccine trials among a sample of men who have sex with men, with and without a history of commercial sex, Rio de Janeiro, Brazil.
de Souza CT; Lowndes CM; Szwarcwald CL; Sutmöller F; Bastos FI
AIDS Care; 2003 Aug; 15(4):539-48. PubMed ID: 14509868
[TBL] [Abstract][Full Text] [Related]
60. Factors associated with willingness to participate in HIV vaccine trials among high-risk populations in South India.
Suhadev M; Nyamathi AM; Swaminathan S; Suresh A; Venkatesan P
AIDS Res Hum Retroviruses; 2009 Feb; 25(2):217-24. PubMed ID: 19239362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
